KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Liabilities and Shareholders Equity (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Liabilities and Shareholders Equity data on record, last reported at $160.4 million in Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 58.17% year-over-year to $160.4 million; the TTM value through Dec 2025 reached $519.9 million, up 52.51%, while the annual FY2025 figure was $160.4 million, 58.17% up from the prior year.
  • Liabilities and Shareholders Equity reached $160.4 million in Q4 2025 per AQST's latest filing, down from $163.6 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $163.6 million in Q3 2025 and bottomed at $51.8 million in Q3 2022.
  • Average Liabilities and Shareholders Equity over 5 years is $88.6 million, with a median of $62.0 million recorded in 2021.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 111.35% in 2024, then dropped 21.07% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $62.0 million in 2021, then decreased by 7.94% to $57.1 million in 2022, then increased by 0.61% to $57.4 million in 2023, then soared by 76.64% to $101.4 million in 2024, then soared by 58.17% to $160.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $160.4 million in Q4 2025, $163.6 million in Q3 2025, and $93.7 million in Q2 2025.